BEAUTYFARM MED (02373) plans to use up to HK$1.2 billion over the next three years to provide returns to company shareholders as appropriate.

BEAUTYFARM MED (02373) announced that, in order to enhance shareholder value, the board of directors has resolved to discretionarily utilize up to a maximum of HK$1.2 billion in the next three years to provide returns to the company's shareholders through the following means: (i) declare annual dividends in accordance with the company's current dividend policy (as disclosed in the announcement of changes to dividend policy dated March 26, 2025, the company will distribute dividends in the form of ordinary shares for the next three complete financial years, with dividends not less than 50% of the company's annual attributable net profit); or (ii) repurchase company shares through market share buy-back methods as authorized at the annual general meeting held on June 27, 2025, and any subsequent authorizations granted by shareholders after the expiration of the current buy-back authorization. The company plans to fund the above program through its internal resources, and anticipates that the implementation of such program will not have a significant adverse impact on the Group's working capital. Shareholders and potential investors are advised that the company has been authorized to repurchase 23,579,556 shares under the current buy-back authorization, and as of the announcement date, the company has repurchased a total of 605,500 shares under the current buy-back authorization.